49 related articles for article (PubMed ID: 17872455)
1. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Qin S; Liu T; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
[TBL] [Abstract][Full Text] [Related]
2. Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition.
Glaros EN; Kim WS; Garner B
Clin Sci (Lond); 2010 Mar; 118(12):727-36. PubMed ID: 20102334
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein A-I anti-tumor activity targets cancer cell metabolism.
Zamanian-Daryoush M; Lindner DJ; Buffa J; Gopalan B; Na J; Hazen SL; DiDonato JA
Oncotarget; 2020 May; 11(19):1777-1796. PubMed ID: 32477466
[TBL] [Abstract][Full Text] [Related]
4. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
Woo MH; Lee HS; Kim J
Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
[TBL] [Abstract][Full Text] [Related]
5. Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.
Di Pino A; DeFronzo RA
Endocr Rev; 2019 Dec; 40(6):1447-1467. PubMed ID: 31050706
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
Xu HR; Zhang JW; Chen WL; Ning ZQ; Li XN
Clin Drug Investig; 2019 Jun; 39(6):553-563. PubMed ID: 31037611
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional perfused human
Kostrzewski T; Cornforth T; Snow SA; Ouro-Gnao L; Rowe C; Large EM; Hughes DJ
World J Gastroenterol; 2017 Jan; 23(2):204-215. PubMed ID: 28127194
[TBL] [Abstract][Full Text] [Related]
8. Effect of urotensin II on apolipoprotein B100 and apolipoprotein A-I expression in HepG2 cell line.
Mohammadi A; Najar AG; Khoshi A
Adv Biomed Res; 2014; 3():22. PubMed ID: 24600602
[TBL] [Abstract][Full Text] [Related]
9. Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells.
Dahabreh DF; Medh JD
Adv Biol Chem; 2012 Aug; 2(3):218-225. PubMed ID: 23616933
[TBL] [Abstract][Full Text] [Related]
10. In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.
He BK; Ning ZQ; Li ZB; Shan S; Pan DS; Ko BC; Li PP; Shen ZF; Dou GF; Zhang BL; Lu XP; Gao Y
PPAR Res; 2012; 2012():546548. PubMed ID: 23150725
[TBL] [Abstract][Full Text] [Related]
11. PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.
Huang JV; Greyson CR; Schwartz GG
J Lipid Res; 2012 Sep; 53(9):1738-54. PubMed ID: 22685322
[TBL] [Abstract][Full Text] [Related]
12. Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.
Millar JS; Ikewaki K; Bloedon LT; Wolfe ML; Szapary PO; Rader DJ
J Lipid Res; 2011 Jan; 52(1):136-42. PubMed ID: 20971975
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.
Zhang LH; Kamanna VS; Ganji SH; Xiong XM; Kashyap ML
J Lipid Res; 2010 Aug; 51(8):2211-22. PubMed ID: 20371549
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.
Haas MJ; Mooradian AD
Drugs; 2010 May; 70(7):805-21. PubMed ID: 20297868
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?
Aljada A; Shah KA; Mousa SA
PPAR Res; 2009; 2009():460764. PubMed ID: 19696948
[TBL] [Abstract][Full Text] [Related]
16. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.
Nakaya H; Summers BD; Nicholson AC; Gotto AM; Hajjar DP; Han J
Am J Pathol; 2009 Jun; 174(6):2007-14. PubMed ID: 19435790
[TBL] [Abstract][Full Text] [Related]
17. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.
Chandalia A; Clarke HJ; Clemens LE; Pandey B; Vicena V; Lee P; Lavan BE; Gregoire FM
PPAR Res; 2009; 2009():706852. PubMed ID: 19404482
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance.
Negro F
PPAR Res; 2009; 2009():483485. PubMed ID: 19132131
[TBL] [Abstract][Full Text] [Related]
19. PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities.
Perreault M; Erbe DV; Tobin JF
PPAR Res; 2008; 2008():125387. PubMed ID: 18989368
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone treatment on endoplasmic reticulum stress response in human adipose and in palmitate-induced stress in human liver and adipose cell lines.
Das SK; Chu WS; Mondal AK; Sharma NK; Kern PA; Rasouli N; Elbein SC
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E393-400. PubMed ID: 18544642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
